Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You seem to have no boundaries. I guess that’s what an anonymous message board gives for the taking.
Bio- Scoping
Reports on Biotech Companies, Alzheimer's and CNS diseaes
From Pat…
https://www.patreon.com/posts/buntanetap-by-in-97163446
Missling seems to be entering panic mode. Other companies being scooped up by big pharma. He seems to be taking a what about us approach almost advertising 273 for Rett and 371 for partnership or even sale. Too late, Chris, your leadership style seems to have failed.
https://www.anavex.com/post/anavex-life-sciences-reports-publication-of-anavex-3-71-in-clinical-journal-confirming-pharmacokinet#:~:text=The%20results%20from%20this%20PK,of%20ANAVEX®3%2D71.
Is ANVS worth a shot? If the trial results are good, yes, an easy 10 bagger. If results are not good, no, down to $1 to $1.5
This surely feels more like gambling than investing. Thoughts?
Here’s what seeking alpha says:
https://seekingalpha.com/article/4663894-annovis-bio-buntanetap-likely-disappoint-upcoming-ad-pd-clinical-trials#comments
It already tanked. I agree, our little message board had nothing to do with it. Maybe our little management team’s lack of experience or ability to bring this disease-altering life-changing medicine to market has something to do with it. Something is going on in this industry that trumps my ability to even begin to figure it out. Brain swelling/bleeding drugs that lack efficacy getting FDA approval is beyond my comprehension. GLTA
Some prolific posters become occasional posters after they dump their shares in the hopes that sp will plummet without their pumping. Their posts will increase once they reload. Looks like we may see the 5’s before this is over, unfortunately.
Hope George is ok. He must be gathering his funds to jump back in here.
Not everybody is losing on this stock:
https://wallmine.com/nasdaq/avxl/officer/2268392/dr-christopher-u-missling.amp
Keep trying. Maybe one of these times you will break through the invisible wall of it’s none of your business attitude we seem to get from the company. Good luck.
I turned my phone on this morning and TempePhil’s post from Dec 2022 came up. If dr Missling’s words have any meaning, the upcoming conference seems a good opportunity to highlight. Thanks for this post TP.
So what sp did you dump at while you were pumping up a storm?
Looks like you missed the dump phase and are now frantically pumping to restore the sp. Forgetaboutit. This coming week, we may see vulture law firms circling about. Maybe not. I certainly hope not. However it plays out, don’t let it get you down. Move forward. Don’t look back. Better days are ahead.
I thought the placebo effect was on those taking the drug during the first four weeks. No?
Dr Missling’s management style or lack of management ability or whatever has fueled his motivation to bring the company to where it is today has bankrupted my ability to have any belief that he could ever lead to success. How are your super responders doing these days, Mr Missling? Seems odd we never hear about those fortunates. Seems odd others are not joining that elite group after having been on this cure-all for so long. Any attempts by you to put a positive spin on the Rett failure or any upcoming AD stuff will fall on deaf ears here.
You seem a bit out of character, George, more neutral than usual but at the same time a bit uncomfortable like someone unsure if it’s dump time or pump time. Just have to wait and see how this plays out tomorrow.
It’s a toss up between legal and ethical. But with ethics gone the way of the dinosaur these days, maybe this is just the new status quo.
Dr Missling’s end of calendar year Bonus is based on the requirements that were set forth by the Board of Directors in the first quarter of 2023. The calendar year ended Dec 31, 2023. Holding back on issuing the Rett Results until this new calendar year, I personally find quite disturbing. It seems unlikely these results fit very well with the requirements set forth by the Board Q1 2023. Maybe issuing the Rett results today, in this new calendar year defines what he meant by “still on track.” Or maybe it is just a coincidence. Maybe the results weren’t finalized until yesterday, a Federal Holiday.
You may be a bit confused. This is Anavex Life Science not Biogen.
Too funny…hahaha!
Maybe you can stop by the boom boom room tomorrow night, George, and ask your bud, Chris, to translate, “still on track” into real time, like days, weeks or months.
It’s not really sprinting now either, as it should. Maybe in a couple of months.
What’s with the Board of Directors never calling out our ceo to account for mis-statements and missed deadlines. With a salary of $3.3 million cash and stock options, it seems he should be held to account for something. Well, on a bright note, the second half of 2023 isn’t over yet. Maybe Great News Tomorrow!
The Boston Red Sox supports the Jimmy Fund, seeking cures for childhood cancer.
Could STAT owner, John Henry, co-owner of the Boston Red Sox develop an appetite for childhood Rett Syndrome or at least tone down the AF attacks on Anavex’s efforts?
John Henry
STAT is produced by Boston Globe Media. Our headquarters is in Boston but we have journalists across the country and also cover international stories. It was launched in November 2015 by John Henry, the owner of Boston Globe Media and the principal owner of the Boston Red Sox.
https://www.statnews.com ›
About Us - STAT health, life science, medicine and biotech news
Remember this Hail Mary pass:
Maybe Missling will flood the market with New Drug Applications (NDA’s). Why not? We’ve had a flood of Clinical Trials going on for years now. The last conference call was nightmare(ish). He knows what we got. He acted like a guy that applied for a loan and doesn’t care if he gets it or not because he knows he has a pile of money sitting in the bank. Hoping for an avalanche of approvals to bring our share price to the 300 dollar(ish) area.
Enough with the ish bs.
Getting the ball to the one yard line is certainly an accomplishment. Getting across the goal line is the success. We have been sitting on the one yard line for far too long, IMO.
“Febish” is the new mantra designed to keep the lid on those of us that question the competence or ability of our ceo to bring this product to market. One more mis-step or missed deadline should be a call for accountability and a demand that our ceo turn his shares and options over to the board for safe-keeping. Those should be merit-based, not the property of a ceo that could walk away and leave us as bag holders. Just my (hopefully sick) opinion.
Ever think about doing stand up comedy? You would have to find better material though because this aien’t funny. Same stuff day after day.
So aspirins are small molecules. I didn’t know that.
Anyone under water with their sp can rest assured the reason is because the current shares are under priced, way, way under priced not because the company doesn’t have a potential if not probable huge upside, IMO. One company I followed, forward split 3 for 1 and then 2 for 1 shortly thereafter on approval of their first product. I can see something similar happening here. Just my opinion.
This CEO guy has to go away NOW! I am not E X C I T E D
There is only one FDA approved drug for agitation for patients with Alzheimer Disease associated dementia. The side effects of Rexulti demand a safer alternative.
https://www.statnews.com/sponsor/2023/10/04/a-silent-struggle-caregiving-for-a-patient-with-agitation-associated-with-dementia-due-to-alzheimers-disease/
I am sorry for the loss of your brother, Nidan. Thanks to both of you for your service to our Country.
It really does look like WGT. Stress and inflammation do seem to lay the groundwork for all types of disease. Our 273 does seem to address those issues.
I seriously posted going the supplement route with 273. We seem to have sufficient patent protection. Do you have any thoughts on that?